Sequella Receives International Support For Phase 2 Clinical Trials Of SQ109, Its Lead Antitubercular Drug Candidate

Published October 20, 2010

Sequella Receives International Support For Phase 2 Clinical Trials Of SQ109, Its Lead Antitubercular Drug Candidate
Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of life-threatening infectious diseases, announced it has signed an agreement with the Ludwig-Maximilians-University (LMU) of Munich to coordinate a European Union grant for Phase 2 clinical trials of SQ109 in adult pulmonary tuberculosis (TB) in seven sites in Africa. The Phase 2 studies, which will …
Read more on Medical News Today

Biotech Stocks: Drug stocks rise; Allergan jumps
Drug stocks gain in afternoon trading as shares of Allergan advance in the wake of additional FDA approval for Botox.
Read more on Market Watch